Dimitri Alvarez, MD
Family Medicine · New York, NYNPI 1114184637
Payments from drug & device makers
Across 366 payments — averaging $18.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- GSK$816
- Lilly USA, LLC$773
- AstraZeneca$587
- Pfizer$525
- AbbVie$402
- plus $2K from 27 others
What the payments were for
- Food & beverage$6,657100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 71 | $1,228 |
| GSK | 45 | $816 |
| Lilly USA, LLC | 40 | $773 |
| AstraZeneca | 32 | $587 |
| Pfizer | 29 | $525 |
| AbbVie(2 entities) | 27 | $402 |
| Exact Sciences | 11 | $287 |
| Merck | 16 | $250 |
| Boehringer Ingelheim | 12 | $231 |
| Johnson & Johnson(2 entities) | 9 | $190 |
| Amgen(2 entities) | 9 | $159 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $146 |
| Biohaven Pharmaceuticals, Inc. | 6 | $122 |
| Novartis | 5 | $113 |
| Teva Pharmaceuticals USA, Inc. | 8 | $110 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $99 |
| Currax Pharmaceuticals LLC | 7 | $87 |
| Kowa Pharmaceuticals America, Inc. | 4 | $85 |
| Bayer | 3 | $67 |
| Astellas Pharma US Inc | 2 | $54 |
| Arbor Pharmaceuticals, Inc. | 3 | $41 |
| Sumitomo Pharma America, Inc. | 2 | $39 |
| Idorsia Pharmaceuticals US Inc | 2 | $36 |
| Lundbeck LLC | 1 | $28 |
| Baxter Healthcare | 1 | $28 |
| Bardy Diagnostics, Inc. | 2 | $26 |
| Antares Pharma, Inc. | 1 | $23 |
| IBSA Pharma Inc. | 1 | $22 |
| Amarin Pharma, Inc. | 1 | $19 |
| Clarus Therapeutics Inc. | 1 | $19 |
| Vertical Pharmaceuticals, LLC | 1 | $18 |
| Nevro Corp. | 1 | $17 |
| Aytu Biopharma, Inc. | 1 | $12 |
How this compares
$6,657 in reported general payments places this provider in the 90th percentile of 4,321 family medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 56 | $72,539 |
| EliquisApixaban | 58 | $55,074 |
| FarxigaDapagliflozin Propanediol | 16 | $19,195 |
| EntrestoSacubitril/Valsartan | 11 | $17,818 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 27 | $17,808 |
| JanuviaSitagliptin Phosphate | 12 | $16,875 |
| Breo ElliptaFluticasone/Vilanterol | 13 | $5,252 |
| Atorvastatin Calcium | 260 | $2,478 |
| Arnuity ElliptaFluticasone Furoate | 11 | $2,251 |
| Levothyroxine Sodium | 143 | $1,988 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 58 | $1,969 |
| Valsartan | 83 | $1,805 |
| Metoprolol Succinate | 120 | $1,549 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 56 | $1,432 |
| Nebivolol Hcl | 21 | $1,403 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $1,228 | $72,53956 claims |
| PfizerEliquis | $525 | $55,07458 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $816 | $25,31251 claims |
| AstraZenecaFarxiga | $587 | $19,19516 claims |
| NovartisEntresto | $113 | $17,81811 claims |
| MerckJanuvia | $250 | $16,87512 claims |
| AbbVieSynthroid | $402 | $1,08913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,321 family medicine providers in New York.
Other family medicine in New York
- Matthew PabisNew York$222K
- Eric BatesNew York$171K
- Alexander BlinskiNew York$159K
- Jason KindtNew York$122K
- Punyadech PhotangthamNew York$107K
- Mahyar EidgahNew York$76K
- Anthony LyonNew York$65K
- Daniel BowersNew York$44K
- Matthew DavisRochester$76.6M
- Frank EderBinghamton$46.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.